About Us

3D Medicines (3DMed), founded in 2010, as a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient.

When the coronavirus 2019 (COVID-2019) outbreak, 3DMed responded rapidly by developing a series of RT-qPCR-based tests (the ANDiS SARS-CoV-2 Detection Kit and the ANDiS SARS-CoV-2 & Influenza A/B Detection Kit) for qualitative detection of SARS-CoV-2 RNA in upper and lower respiratory specimens collected from individuals who meet the CDC criteria for SARS-CoV-2 testing.
 

Learn more

CORE BUSINESS

LDT Business

Learn more

IVD Business

Learn more

Press Center

Find 3DMed's lastest news and recent activities

Why is nucleic acid testing the gold standard?

Why is nucleic acid testing the gold standard?

March 27,2020
3DMed SARS-Cov-2 Detection Kit Receives CE Mark

3DMed SARS-Cov-2 Detection Kit Receives CE Mark

March 23,2020

Support and cooperation

For business cooperation, product consultation, technical support, etc., please contact us!

CONTACT US
contact information
Questions or Comments